Clinical Trial: ADCT-402-105

Trial Status: Open
Disease Type: Lymphoma
Trial ID ADCT-402-105
Sponsor ID LOTIS-7

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Principal Investigator
Mitul Gandhi, MD
1 Location


Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID DR-01-ONC-001
Sponsor ID Dren Bio

A Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Trial ID 11282
Sponsor ID SGN35-015

A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkins Lymphoma and CD30-expressing Peripheral T-Cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Therapy

Principal Investigator
Dipti Patel-Donnelly, MD
4 Locations